Osivax Secures EUR 8 Million of Financing through a Series A Round to Develop Novel Universal Flu Vaccines and Expand oligoDOM® Technology Platform — Company to establish new subsidiary office in Liege, Belgium — Lyon, France – July 10, 2019 – Osivax announced today that it has secured EUR 8 million of financing through a Series …
Continuer la lecture « Osivax secures EUR 8 Million of Financing through a Series A Round »
Paul Willems’ appointment will strengthen Osivax’s capacities to design and implement an ambitious and impactful clinical development plan for its vaccines pipeline and especially the “universal” flu vaccine program Lyon, France – January 31st, 2019 – Osivax, a clinical stage biopharmaceutical company currently focused on the development of a breakthrough “universal” influenza vaccine program, announced today …
Continuer la lecture « Osivax appoints Dr. Paul Willems as Chief Medical Officer »
Osivax announces that the Belgian health authority approved the initiation of a first-in-human clinical trial evaluating the safety and immunogenicity of OVX836 in healthy volunteers Lyon, France – June 4, 2018 – Osivax, a clinical stage biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, announced today that the Belgian health authority …
As DKFZ’s HPV vaccine candidate based on Osivax’s technology platform (OVX313) reports promising pre-clinical results, a second license agreement was signed Lyon, France – April 17, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a universal influenza vaccine candidate, announced today the reinforcement of its collaboration with the world-renowned German Cancer Research …
Prof. Almond’s appointment will strengthen Osivax’s capacities to drive, position and prioritize pipeline development and especially OVX836, a broad-spectrum influenza vaccine Lyon, France – February 19th, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a breakthrough influenza vaccine, announced today that the Company is strengthening its management team with the appointment of …
This recruitment brings strategic capabilities to drive the development of Osivax’s lead candidate, a breakthrough influenza vaccine Lyon, France – January 24th, 2018 – Osivax, a biopharmaceutical company currently focused on the development of a breakthrough influenza vaccine, announced today that the Company is strengthening its management team with the appointment of Dr. Delphine Guyon-Gellin as …
